
|Articles|September 1, 2007
- Volume 0 0
WORLD HEALTH ORGANIZATION STUDIES TRAVEL RISKS
Author(s)Anna D. Garrett, PharmD, BCPS, CPP
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
Advertisement
In 2001, the World Health Organization (WHO) began a 2-phase project called the WHO Research Into Global Hazards ofTravel (WRIGHT) Project. The objectives of the project were toconfirm that the risk of venous thromboembolism (VTE) isincreased by air travel and to determine the magnitude of risk,the effect of other factors on the risk, and the effect of preventivemeasures on risk.
The key findings of the WRIGHT Phase I report include the following:
- The risk of VTE roughly doubles with flights greater than 4 hours and increaseswith longer flights or repeated flights within a short period of time.
- Overall, the absolute risk of VTE appears to be about 1 in 6000 healthy individuals,but the risk is primarily concentrated in patients with hypercoagulable conditions,those using birth control pills, or those who have other risk factors such asobesity, extremes of height (less than 5?2? or greater than 6?2?), older age, and cardiovasculardisease.
- The VTE risk is greatest immediately following a flight, but some risk persistsfor several weeks afterward.
Articles in this issue
almost 19 years ago
Calming the Symptoms of Menopausealmost 19 years ago
Zoster Vaccinealmost 19 years ago
pharmacy TECHNOLOGY productsalmost 19 years ago
health-systems PRODUCT newsalmost 19 years ago
can you READ these Rxs?almost 19 years ago
can you READ these Rxs?almost 19 years ago
Generic Times Product Newsalmost 19 years ago
compounding HOTLINEalmost 19 years ago
Human HRT Leads Compounding Renaissancealmost 19 years ago
Prescription-overdose Deaths Surpass Car-accident DeathsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADA 2026: Factors Associated With GLP-1 RA Nonresponse in T2D—and What Pharmacists Should Screen For
2
ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk
3
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
4
The Hidden Reimbursement Crisis in Medicare’s Drug Price Negotiation Program
5






































































































































